Kornimate/medical-research-clean huggingface dataset:
characterization and outcome of children with leukodystrophy: an observational study at sohag university hospital

Conditions: Children With Leukodystrophy

Summary: leukodystrophies are heterogeneous genetic disorders characterized by the selective involvement of white matter in the central nervous system (cns) (1, 2). inherited leukodystrophies are diseases of the myelin, including abnormal myelin development, hypomyelination, or degeneration of myelin (3, 4). most of these disorders fall into one of three categories; lysosomal storage diseases, peroxisomal disorders, and diseases caused by mitochondrial dysfunction and each leukodystrophy has distinctive clinical, biochemical, pathologic, and radiologic features (5).


Eligibility criteria:
inclusion criteria: * the patients fulfilling all the following criteria will be included: 1. age ≤ 18 years. 2. the presence of typical clinical, biochemical, and neuroimaging features of leukodystrophies. exclusion criteria: * 1- children who have coexistent genetic disorders. 2- children who have cerebral malformations. 3- history of perinatal asphyxia. 4- history of head trauma or intracranial hemorrhage. 5- acquired cns myelin disorders, such as multiple sclerosis and related acquired demyelinating processes, infectious and post-infectious white matter damage, toxic injuries and non-genetic vascular insults.
thc and cbd: a controlled human study probing a harm reduction strategy

Conditions: Abuse, Drug; Pain

Summary: the purpose of this research is to assess the impact of cbd on the effects of thc.

some evidence indicates that cannabidiol (cbd), a non-intoxicating cannabis component, might mitigate certain effects of thc. this study will examine possible roles for cbd in modulating thc's adverse and analgesic effects.

Eligibility criteria:
inclusion criteria: * male or non-pregnant and non-lactating females aged 21-55 years * report cannabis use 1-7 days per week over the month prior to screening * not currently seeking treatment for their cannabis use * history of inhaled cannabis use * have a body mass index from 18.5 - 34 kg/m2 * able to perform all study procedures * must be using a contraceptive (hormonal or barrier methods) exclusion criteria: * meeting dsm-v criteria for severe cannabis use disorder (cud) or any substance use disorder other than nicotine, caffeine, mild or moderate cud * evidence of severe psychiatric illness (e.g. mood or anxiety disorder with functional impairment or suicide risk, schizophrenia) judged by the study physician (and pi) to put the participant at greater risk of experiencing adverse events due to completion of study procedures, interfere with their ability to participate in the study, or their capacity to provide informed consent. * report using other illicit drugs in the prior 4 weeks * current pain * pregnancy * currently enrolled in another research protocol * not using a contraceptive method (hormonal or barrier methods) * insensitivity to the cold water stimulus of the cold pressor test * any disorders that might make cannabis administration hazardous as determined by evaluation physician after review of all medical assessments along with medical history. * not able to speak and read english

Keywords: cannabis thc cbd
vitamin d deficiency of couples and infertility

Conditions: Vitamin D Deficiency; Infertility; Couples; In-vitro Fertilization

Summary: between march 2016 and march 2017, we performed a large retrospective, non-interventional, single-center cohort study and measured 25(oh)d3 plasma levels prior to ovarian stimulation in couples who underwent ivf/icsi.and we analysed the correlation of vitamin d status and reproductive capacity .

before conducting ovarian stimulation, all couples must conduct preoperative routine examination such as routine blood test, blood group examination and infectious disease examination. we collected 2ml remaining blood from the examination by use of sodium heparin, which then conducted 1,25(oh)2d3 assay by liquid chromatography-tandem mass spectrometry. all patients underwent a standardized ovarian stimulation regimen, oocyte retrieval, and fertilization, followed by a planned fresh or frozen embryo transfer.normal fertilization rate was defined as the presence of two pronuclei (2pn) at the time of fertilization assessment, 16-19 h after icsi or conventional insemination. the percentage of top quality embryos was defined as the percentage of top quality embryos among the total number of 2pn embryos. blastocyst forming rate was calculated as number of formed blastocysts devided by number of cultured blastocysts.

Eligibility criteria:
inclusion criteria: * couples who underwent ivf/icsi. exclusion criteria: * sperm or egg donation, pgd or pgs,tesa or pesa, ovum frozen ,no oocyte for fertilization.
midline programme - vascular nursing team

Conditions: Inflammation; Local; Infection

Summary: integration of the vascular nursing team of the department of haematooncology, university hospital ostrava for the needs of all clinical departments of the hospital. assessment of local signs of inflammation in patients of the department of haematooncology and other clinical departments of the university hospital ostrava.

the study subjects were indicated by a physician for midline catheter insertion. prior to insertion of the catheter, the study subjects were fully informed and signed the informed consent with participation in the study. local signs of inflammation were recorded in the study subjects, together with basic demographic characteristics (age, sex, diagnosis), and complications during catheter insertion, the number of days when the midline catheter was inserted, number of changes of the dressings, presence of neutropenia in the study subjects and the score of local inflammation according to madonna. * degree 0- no pain or reaction in the surrounding * degree 1 - pain only, no reaction in the surrounding * degree 2 - pain and reddening * degree 3 - pain, reddening, swelling or painful stripe along the vein * degree 4 - puss, swelling, reddening and painful stripe along the vein the investigators also observed on which day the first signs of infection appeared.

Eligibility criteria:
inclusion criteria: * insertion of midline catheter by nurses from the vascular nursing team * age over 18 years exclusion criteria: - inability to insert the midline catheter

Keywords: midline catheter vascular nursing team
aquagenic wrinkling prediction

Conditions: Aquagenic Wrinkling of Palms; Carrier State

Summary: the goal of this observational study is to determine whether an aquagenic wrinkling procedure (i.e., soaking hands in a water bath for up to 20 minutes) can be used as a screening tool for cystic fibrosis carrier status. participants will complete one visit where they will undergo an aquagenic wrinkling procedure to see how their hands respond.


Eligibility criteria:
inclusion criteria: * interested in participating in other cf carrier-related research studies. exclusion criteria: * cf patient status * unable to speak english * unable to provide written informed consent * prisoner status * an open wound on either hand * a tattoo on either hand * missing any portion of either hand * diagnosis of diabetes * diagnosis of hyperhidrosis * diagnosis of raynaud's disease * diagnosis of atopic dermatitis * regularly taking ace inhibitors or angiotensin receptor blockers
diet and omega-3 intervention trial on atherosclerosis

Conditions: Atherosclerosis

Summary: the study was actuated to evaluate the effects of a 3-year intervention with diet and/or very long chain omega-3 (vlc n-3 pufa), in a randomized 2x2 factorial design on the progression of atherosclerosis in a high risk population. a total of 563 elderly men were included and randomized to receive usual care and vlc n-3 placebo capsules (control group), dietary advice and vlc n-3 placebo capsules, usual care and vlc n-3 capsules, and finally both vlc n-3 capsules and dietary advice. the evaluation of atherosclerosis were i) ultrasound measurement of carotid intima media thickening ii) pulse wave propagation time iii) circulating biomarkers of atherosclerosis.

the basis for recruitment was a follow up of subjects participating in the oslo diet and anti smoking study (1972-1977) characterised as hypercholesterolemic in 1972. measurements of the outcome variables were performed at baseline and after 36 m; blood sampling also after 6 and 18 m. in addition to the main outcome variables, a biobank was established for future analyses. clinical events were also recorded.

Eligibility criteria:
inclusion criteria: * elderly men with long standing hypercholesterolemia (cholesterol \> 6.45 mmol/l and \< 8.00 mmol/l) with or without coronary heart disease. exclusion criteria: * cholesterol \> 8.00 mmol/l, blood pressure \> 170/100 * uncontrolled hypertension * socially or otherwise unsuitable subjects * anticipated non compliance * other major non cardiac illness expected to reduce life expectancy or interfere with study participation.
clinical trial to evaluate the efficacy and safety of da-5219 in patients with acute or chronic gastritis

Conditions: Gastritis Acute; Gastritis Chronic

Summary: this study is to evaluate the efficacy and safety of da-5219 in patients with acute or chronic gastritis


Eligibility criteria:
main inclusion criteria: * men or women aged ≥ 19 years and ≤ 75 years * subjects who diagnosed with acute or chronic gastritis by upper gastrointestinal endoscopy within 7days prior to the randomization * subjects who have one or more erosions identified on upper gastrointestinal endoscopy within 7days prior to the randomization * subjects who voluntarily signed a consent form main exclusion criteria: * ineligible for upper gastrointestinal endoscopy * subjects with active or healing gastroduodenal ulcer, reflux esophagitis, barrett's esophagus, or gastroesophageal varices identified on upper gastrointestinal endoscopy within 7days prior to the randomization * subjects with hypersensitivity to investigational drugs and similar drugs * pregnant or breastfeeding women
sars-cov-2 (covid-19) detection using the breath analizer terasystem

Conditions: COVID19

Summary: the purpose of the study is to verify the sensibility and accuracy of a rapid detection test for sars-cov-2 in breath samples analyzed by the breath detector analyzer terasystem, comparing with pcr tests.

biosafety technologies has developed a rapid detection test to clear people of covid-19. a person can undergo an easy non-invasive test, to determine if they are: covid-19 clear (negative) or infected (positive). the user-friendly process does not involve medically trained personnel. the study will compare terasystem test results against pcr test results. persons participating will be persons having a pcr test as part of the health system and consenting to participate.

Eligibility criteria:
inclusion criteria: older than 7 years odf age able to provide informed consent able to take the breath test exclusion criteria: younger than 7 years of age unable to provide informed consent unable to take the breath test

Keywords: sars-cov-2, coronavirus testing
effectiveness of two self assessment tools: kios-bipolar or emoods

Conditions: Bipolar Disorder

Summary: the goal of this project is to complete the development of a patient-centered software system and mobile app to assist in managing bipolar disorder. in phase i, the investigators developed a novel computational tool known as kios. based on concepts from nonlinear systems (chaos) theory, kios tracks multiple interacting symptoms to determine the precise state of a bd patient. once the patient's state is identified and the trajectory of the patient is established, kios produces advice specific to the patient's condition to help manage the course of the disease. to demonstrate the usability of the software, kios was converted to an online tool with mobile access. twenty bipolar patients evaluated kios in a twelve week field trial. no technical problems with the software were observed and results showed that patients had significantly more reductions in symptom severity than increases. the development of this innovative tool to help patients self- manage bd has the potential to have a profound impact on public health and achieve significant commercial success.

this phase ii study has the specific aim of evaluation of kios-bipolar in a randomized, open 52 week effectiveness study of 120 bipolar subjects in current treatment at three socioeconomically diverse academic health science centers. concurrent with this clinical effectiveness study, the research team, funded by the same nih grant,will refine prototype software and integrate data security and establish quality standards into the kios-bipolar system. the clinical trial will: assess sensitivity of k-b assessed improvement or worsening by comparison with assessment by biss-self and biss-42.

Eligibility criteria:
inclusion criteria: 1. male or female outpatients 18 years of age or older 2. bipolar i or ii disorder as assessed by mini 6.0 3. in psychiatric outpatient treatment at uthscsa, university of louisville, or lindner center of hope, mason ohio 4. currently taking mood stabilizer or second generation antipsychotic for 4 weeks or longer 5. ability to access kios-bipolar or emoods (via computer, smartphone or tablet) exclusion criteria: 1. unwilling or unable to comply with study requirements 2. renal impairment (serum creatinine \>1.5 mg/dl 3. if on thyroid medication must be euthyroid for at least 1 month 4. drug/alcohol dependence within the past 30 days

Keywords: bipolar self assessment prospective randomized trial
vtx-2337 in combination with radiotherapy in patients low-grade b-cell lymphomas

Conditions: Low Grade B Cell Lymphoma

Summary: this study is to determine the safety and effectiveness of vtx-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade b-cell lymphoma. patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of vtx-2337 over the course of 3 months.


Eligibility criteria:
major inclusion criteria: * low grade b cell lymphoma * 1 or more sites of disease appropriate for intratumoral injection * measurable disease other than the injection site * performance status of 1 or better * adequate bone marrow, renal and hepatic function * no active autoimmune disease or systemic immunosuppressive drugs * life expectancy \> 4 months exclusion criteria: * known hiv * known brain metastases * malignancy within last 5 yrs (basal cell or non-invasive squamous cell carcinoma ok) * anticoagulation therapy other than 325mg qd asa * significant cardiovascular disease * pregnant or nursing

Keywords: b cell lymphoma
evaluation of increased fruits and vegetables consumption in chronic kidney disease

Conditions: Chronic Kidney Diseases

Summary: this study aims to investigate the feasibility of increasing dietary consumption of a rich variety of fruits and vegetables (including those that are potassim-rich) in patients with chronic kidney disease through use of nutritional counselling and hyperkalemia management with patiromer

adult patients ages 18 and older with a diagnosis of chronic kidney disease will be given a diet plan that consist of an increase of fruits and vegetables. baseline data will be collected after the subject has signed the consent and their most recent egfr and potassium level that is within 90 days has been reviewed to determine they are within the inclusion criteria. based on the approved patiromer (veltassa) package insert the subject will begin to take daily. during this control period of two weeks, the subject will document their normal daily consumption of fruits and vegetables in a provided food diary. on the second week, patient will receive dietary/nutritional counseling on the importance of potassium-rich fruits and vegetables. they will be instructed to increase their fruit and vegetable intake based on personal preferences and nutritional guides located inside the food diary. choices will be documented daily in the supplied food diaries. the bowel diary will be classified according to the bristol stool chart and quality of life. nutrition survey questionnaire will be documented in that supplied log. at each subsequent visit, food diaries will be reviewed to evaluate fruit and vegetable consumption, vital signs will be documented and labs collected to measure effects on potassium metabolism. bowel habits and questionnaires will be completed by the subject to determine how their diet has affected their quality of life. patiromer (veltessa) dosing will be adjusted based on their serum potassium values following the approved drug brochure guidelines and at the discretion of the investigator. subject will return to the clinic at specified time points up to 52 weeks on study. the patient can continue veltassa while in the follow up period until week 52 at the discretion of the principle investigator.

Eligibility criteria:
inclusion criteria: 1. adult patients ≥ 18 years of age with chronic kidney disease and hyperkalemia 2. chronic kidney disease is defined as egfr 15-44ml/min/1.73m2 3. documented hyperkalemia which is defined as serum potassium ≥ 5.0 mmol/l during the last 90 days 4. diet evaluation for hyperkalemia (serum potassium ≥ 5.0) during the last 90 days 5. patients receiving rass inhibitors, beta-blockers, or diuretics to be on stable doses for 2 weeks 6. patients already receiving patiromer are eligible exclusion criteria: 1. patients with a known allergy to patiromer 2. patients currently taking other potassium controlling agents.
effect of nmn (nicotinamide mononucleotide) on diminished ovarian reserve (including premature ovarian insufficiency)

Conditions: Diminished Ovarian Reserve; Premature Ovarian Insufficiency

Summary: the purpose of the study is to understand the effect of nicotinamide mononucleotide (nmn) on patients with diminished ovarian reserve (including premature ovarian insufficiency).

this study aims to evaluate the effects of nmn on reproductive endocrine, immune homeostasis, and reproductive outcomes in women with dor (including poi), and to explore its underlying mechanisms to provide the intervention strategies for dor (including poi).

Eligibility criteria:
inclusion criteria: 1. individuals who are 20 to 40 years old. 2. the concentrations of anti-mullerian hormone \< 1.1 ng/ml, the values of antral follicle count range from less than 5 to less than 7 and two recordings of serum concentrations of day-3 follicle-stimulating hormone (fsh) ≥10 iu/l. 3. individuals who can insist on continuous monitoring in the outpatient clinic. 4. individuals who are not participating in other research projects currently or 3 months before the intervention. exclusion criteria: 1. individuals who are during pregnant, lactation or menopause. 2. individuals who had non-46-xx karyotype, or attributed to known genetic etiology. 3. individuals who had pelvic surgery. 4. cancer patients or receiving chemo/radiotherapy treatment within the past 5 years. 5. individuals who need regular medication to treat chronic diseases such as diabetes, hypertension, gout, hyperuricemia, etc. 6. individuals who currently receiving weight-loss drugs or surgery or within the past 2 months. 7. use of medications or traditional chinese medicine that affect hormone levels, appetite, carbohydrate absorption, and metabolism within the past 3 months. 8. individuals who take niacin, nicotinamide, or other vitamin b3-related supplementation, or other supplementation such as coenzyme q10, vitamin e currently or within the past 3 months. 9. use of antibiotics, probiotics, or prebiotics that affect the flora within the past 3 months. 10. individuals with severe liver diseases or kidney disease that are ineligible to participate in the study. 11. a medical history of severe cardiovascular and cerebrovascular diseases. 12. individuals who currently suffer from severe gastrointestinal diseases or undergo gastrointestinal resection that may affect nutrient absorption. 13. individuals who drink more than 15g of alcohol per day or have a smoking habit. 14. individuals who need drug treatment for any mental illness such as epilepsy and depression. 15. individuals who suffer from infectious diseases such as hepatitis b, active tuberculosis, aids, etc. 16. unable or unwilling to follow the study protocol.
intranasal versus intravenous drug in painful procedure for outpatient oncologic participants

Conditions: Pediatric Cancer; Analgesia; Procedural Pain

Summary: pain is a vital sign that depends on personal experience involving different factors such as previous sensory and emotional experience, age, spiritual and cultural aspects, that makes it harder to evaluate, especially in young children. pain control is important to diminish the anxiety of the child and family, also this is more important in patients who require procedure and treatment that are more painful, like oncological and hematological patients. the study aims to measure if the intranasal drugs (dexmedetomidine and fentanyl) has the same outcomes when compared with intravenous drug (ketamine and midazolam), but with less side effects. the participants are patients from an oncologic outpatient, that will be submitted to cerebrospinal fluid puncture, myelogram or both will be randomized assigned to both groups. the study will compare physiological variables ( heart rate, respiratory rate and blood pressure) and sedation and pain scales to see if its work properly. the study purpose is to evaluate if intranasal drug works in the same way with less side effects comparing with the usual treatment.


Eligibility criteria:
inclusion criteria: * patients with oncohematological diseases that requires cerebrospinal fluid, myelogram or both for staging and monitoring their treatment ( leukemia, lymphoma, solid tumors and bone marrow aplasia) * patients who is undergoing to collect cerebrospinal fluid, myelogram or both; * aged between two and eight years; * absence of tumor recurrence. exclusion criteria: * previous neurologic disease; * using of opioid previously; * neurological developmental delay

Keywords: fentanyl dexmedetomidine
resistance training in children

Conditions: Healthy

Summary: the project is going to examine the effects of resistance exercise training in prepubescent youth on skeletal muscle strength and lipid content.


Eligibility criteria:
inclusion criteria: * healthy volunteer males and females ages 8 - 10 years. exclusion criteria: * no history or ongoing neuromuscular diseases. * no history or ongoing musculoskeletal injuries. * no history or ongoing disease that effects metabolism.

Keywords: exercise muscle cross-sectional area intramyocellular lipids extramyocellular lipids strength
primary tumor resection for m1a stage lung cancer

Conditions: Lung Cancer Metastatic; Surgical Resection

Summary: this is a clinical trial from eastern cooperative thoracic oncology project (ectop), numbered as ectop-1023. this study aims to explore the safety and efficacy of primary lesion resection in the treatment of m1a stage lung cancer with pleural dissemination found during surgery, and to more accurately evaluate whether primary lesion resection can improve the os and quality of life of the corresponding patients.


Eligibility criteria:
inclusion criteria: 1. volunteer to participate in clinical research, willing to follow and able to complete all trial procedures; 2. aged 18-80 years (including critical values) when signing the informed consent form; 3. ecog score 0 or 1; 4. no previous lung cancer surgery; 5. intraoperative or postoperative pathological confirmation of m1a stage lung cancer; 6. occult pleural metastasis found during surgery; 7. preoperative lymph node staging is cn0; 8. first-time treatment and no radiotherapy or chemotherapy. exclusion criteria: 1. the lesion cannot be completely removed surgically; 2. cytological or histological pathology confirms other lung malignancies other than lung cancer; 3. patients who have undergone lung cancer surgery before; 4. patients who have received radiotherapy or chemotherapy and are not treatment-naive patients.